for "nightly business report," i'm kaela tausche, bayonne, new jersey. >>> and to read more about the infrastructure permitting maze, head to our website, nbr kam. >>> bristol-myers squibb enters one of the largest drug collaboration deals ever. that's where we begin tonight's market focus. bristol-myers will pay nectar therapeutics for the right to its experimental cancer treatment. they could also receive an additional $2 billion from bristol-myers. shares climbed 2% to 65.3a shares nectar popped 11% to $84. the advertising firm interpublic group reported revenue growth in this quarter that easily surpasseda expeions. it reported weaker client spending for the year but expects that to verse course this year. they forecast organic revenue to rise as much as 3% this year. the share rose 10% to $27.49 increased marketing and a growing user base trnslated to higher profits over at groupon. hey weren't high enough and theyissed analyst's estimates. groupon continued to scale back its presence some international markets and issued a disappointing forecast. the shares plunged 9% to $4.71.